Caribou Biosciences Inc - Asset Resilience Ratio
Caribou Biosciences Inc (CRBU) has an Asset Resilience Ratio of 60.32% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Caribou Biosciences Inc current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2025)
This chart shows how Caribou Biosciences Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see CRBU current and non-current assets.
Liquid Assets Composition Over Time
This chart breaks down Caribou Biosciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Caribou Biosciences Inc long-term investment allocation to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $86.12 Million | 60.32% |
| Total Liquid Assets | $86.12 Million | 60.32% |
Asset Resilience Insights
- Very High Liquidity: Caribou Biosciences Inc maintains exceptional liquid asset reserves at 60.32% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Caribou Biosciences Inc Industry Peers by Asset Resilience Ratio
Compare Caribou Biosciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
F:A71 |
Biotechnology | 0.00% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX |
Biotechnology | 2.58% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Kailera Therapeutics, Inc. Common Stock
NASDAQ:KLRA |
Biotechnology | 64.92% |
|
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX |
Biotechnology | 78.22% |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068 |
Biotechnology | 20.87% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
Annual Asset Resilience Ratio for Caribou Biosciences Inc (2019–2025)
The table below shows the annual Asset Resilience Ratio data for Caribou Biosciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 72.41% | $126.98 Million | $175.37 Million | +10.73pp |
| 2024-12-31 | 61.68% | $193.24 Million | $313.31 Million | -2.57pp |
| 2023-12-31 | 64.24% | $277.67 Million | $432.21 Million | +13.59pp |
| 2022-12-31 | 50.65% | $189.32 Million | $373.76 Million | +20.04pp |
| 2021-12-31 | 30.61% | $135.41 Million | $442.36 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $36.05 Million | -- |
| 2019-12-31 | 13.56% | $8.40 Million | $61.93 Million | -- |
About Caribou Biosciences Inc
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD… Read more